UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F26475821%3A_____%2F12%3A%230000154" target="_blank" >RIV/26475821:_____/12:#0000154 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.ueg.eu/fileadmin/user_upload/documents/Week13/UEG_Week_2012.Final_Programme.pdf" target="_blank" >http://www.ueg.eu/fileadmin/user_upload/documents/Week13/UEG_Week_2012.Final_Programme.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS

Popis výsledku v původním jazyce

Poster: Patients with advanced stages of malignant tumors have elevated levels of circulating free DNA (cellfree DNA cfDNA) in peripheral blood. Under certain condition, examination of tumor cfDNA can substitute conventional tissue profiling from biopsies or resections with minimal invasivity. AIMS&METHODS: In the present work we demonstrate practical use of cfDNA examination in predictive KRAS testing as well as for monitoring of therapy response and the long term course of the disease. The initial group consisted of 204 patients in various confirmed stages of colon and rectal cancers undergoing either surgical treatment or chemotherapy. We have acquired tissue samples from primary and/or metastatic sites. In addition, plasma samples were acquired periodically over the course of the disease treatment. Mutation-based cfDNA detection was performed using a ?classic? panel of somatic mutations covering APC, KRAS, BRAF, PIK3CA and TP53 genes. RESULTS: The cfDNA detection rates were in corr

Název v anglickém jazyce

UTILITY OF CELL-FREE TUMOR DNA IN CLINICAL MANAGEMENT OF COLORECTAL CANCER PATIENTS

Popis výsledku anglicky

Poster: Patients with advanced stages of malignant tumors have elevated levels of circulating free DNA (cellfree DNA cfDNA) in peripheral blood. Under certain condition, examination of tumor cfDNA can substitute conventional tissue profiling from biopsies or resections with minimal invasivity. AIMS&METHODS: In the present work we demonstrate practical use of cfDNA examination in predictive KRAS testing as well as for monitoring of therapy response and the long term course of the disease. The initial group consisted of 204 patients in various confirmed stages of colon and rectal cancers undergoing either surgical treatment or chemotherapy. We have acquired tissue samples from primary and/or metastatic sites. In addition, plasma samples were acquired periodically over the course of the disease treatment. Mutation-based cfDNA detection was performed using a ?classic? panel of somatic mutations covering APC, KRAS, BRAF, PIK3CA and TP53 genes. RESULTS: The cfDNA detection rates were in corr

Druh

O - Ostatní výsledky

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

<a href="/cs/project/NS9809" target="_blank" >NS9809: Využití nových molekulárně-genetických metod pro časný záchyt progrese onemocnění u pacientů s primárně resekabilním kolorektálním karcinomem na základě vyšetření cirkulujících nádorových buněk a volných nádorových nukleových kyselin</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2012

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů